La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Unity Biotechnology Gestion

Gestion contrôle des critères 3/4

Le PDG Unity Biotechnology's est Anirvan Ghosh, nommé en Mar2020, a un mandat de 4.42 ans. La rémunération annuelle totale est $ 1.26M, composée du salaire de 48.3% et des bonus 51.7%, y compris les actions et options de la société. détient directement 0.43% des actions de la société, d'une valeur de $ 103.35K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.4 ans et 6 ans.

Informations clés

Anirvan Ghosh

Directeur général

US$1.3m

Rémunération totale

Pourcentage du salaire du PDG	48.3%
Durée du mandat du directeur général	4.5yrs
Propriété du PDG	0.4%
Durée moyenne d'occupation des postes de direction	4.3yrs
Durée moyenne du mandat des membres du conseil d'administration	6.1yrs

Mises à jour récentes de la gestion

Recent updates

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Jul 12

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Dec 22

A Look Inside Unity Bio's Transition To An Ophthalmology Company

Nov 27

Analyse de la rémunération des PDG

Comment la rémunération de Anirvan Ghosh a-t-elle évolué par rapport aux bénéfices de Unity Biotechnology?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$1m	US$609k	-US$40m
Sep 30 2023	n/a	n/a	-US$35m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$2m	US$580k	-US$44m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$59m
Mar 31 2022	n/a	n/a	-US$64m
Dec 31 2021	US$4m	US$562k	-US$61m
Sep 30 2021	n/a	n/a	-US$70m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$82m
Dec 31 2020	US$7m	US$417k	-US$94m

Rémunération vs marché: La rémunération totale de Anirvan ($USD 1.26M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de Anirvan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Anirvan Ghosh (60 yo)

4.5yrs

Titularisation

US$1,260,838

Compensation

Dr. Anirvan Ghosh, Ph D., serves as Chief Executive Officer and Director of Unity Biotechnology, Inc. since March 30, 2020. Dr. Ghosh had been Senior Vice President, Head of Research and Early Development...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Anirvan Ghosh	CEO & Director	4.5yrs	US$1.26m	0.43% $ 105.5k
Nathaniel David	Co-Founder & Executive Director	13.7yrs	US$55.20k	0.35% $ 85.5k
Lynne Sullivan	CFO & Head of Corporate Development	4.1yrs	US$771.59k	0.33% $ 79.5k
Alexander Nguyen	Chief Legal Officer	3.5yrs	US$677.80k	0.022% $ 5.4k
Jan van Deursen	Founder	13.7yrs	pas de données	pas de données
Daohong Zhou	Founder	13.7yrs	pas de données	pas de données
Przemyslaw Sapieha	Chief Scientist	3.6yrs	pas de données	pas de données
Alicia Tozier	Chief Strategy Officer	less than a year	pas de données	pas de données

4.3yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe de direction de UBX est considérée comme expérimentée (ancienneté moyenne 4.4 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Anirvan Ghosh	CEO & Director	4.5yrs	US$1.26m	0.43% $ 105.5k
Nathaniel David	Co-Founder & Executive Director	12.8yrs	US$55.20k	0.35% $ 85.5k
Camille Samuels	Independent Director	9.5yrs	US$65.70k	0.0060% $ 1.5k
Paul Berns	Lead Independent Director	6.5yrs	US$92.70k	0.0019% $ 471.5
Keith Leonard	Chairman	8.7yrs	US$85.20k	0.13% $ 31.2k
Margo Roberts	Independent Director	5.8yrs	US$59.20k	0% $ 0
Michael Samar	Independent Director	2.3yrs	US$70.20k	0% $ 0
Gilmore O'Neill	Independent Director	3.8yrs	US$60.20k	0% $ 0

6.1yrs

Durée moyenne de l'emploi

58.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de UBX sont considérés comme expérimentés (ancienneté moyenne 6 ans).

Unity Biotechnology Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy Officer

Insufficient new directors

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Insufficient new directors

UNITY Biotechnology Announces Board Changes

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

Recent updates

UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy Officer

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Price target decreased by 10% to US$6.00

Insufficient new directors

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

Unity Biotechnology, Inc. announced delayed annual 10-K filing

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss

Insufficient new directors

Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

New major risk - Financial position

Price target decreased by 13% to US$6.80

UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

New major risk - Revenue and earnings growth

Price target increased by 12% to US$8.80

Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)

Price target increased by 8.8% to US$7.83

Price target decreased to US$38.00

Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular Edema

Price target increased to US$75.17

Price target increased to US$90.00

UNITY Biotechnology falls 7% on reverse stock split

Price target increased to US$7.83

Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular Degeneration

Unity Biotechnology cuts stock sales agreement in half to $25M

Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular Edema

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

UNITY Biotechnology Announces Board Changes

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

Price target increased to US$7.50

UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degenera

Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, Inc

Price target increased to US$7.50

Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022

Chief Medical Officer notifies of intention to sell stock

A Look At Unity's UBX1325 Phase 1 Results

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell 3000E Index

Price target increased to US$6.86

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Price target increased to US$6.20

Unity Biotechnology, Inc. Appoints Alexander Nguyen as General Counsel

Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye Diseases

New 90-day high: US$7.51

Unity Biotechnology, Inc. Appoints Przemyslaw (Mike) Sapieha as Chief Scientific Advisor

New 90-day high: US$6.47

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Unity Biotechnology Announces Executive Changes

A Look Inside Unity Bio's Transition To An Ophthalmology Company

New 90-day high: US$4.78

Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

New 90-day low - US$2.94

Price target lowered to US$5.67

Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

New 90-day high - US$9.96

Price target raised to US$23.33

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell Microcap Value Index

Analyse de la rémunération des PDG

PDG

Titularisation